rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ABEO
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Abeona Therapeutics: My 'Buy The Dip' Call Backfired On Q3 Earnings: I'm Downgrading To Hold
      6h agoSeeking AlphaABEO
      Abeona Therapeutics Inc. (ABEO) Presents at Stifel 2026 Healthcare Conference 2026 - Slideshow
      Nov 17Seeking AlphaABEOSF
      Abeona Therapeutics director Faith Charles buys $34,348 in shares
      Nov 16Investing.comABEO
      Abeona Therapeutics (ABEO) Stock Sees Fair Value Falls As Zevaskyn Ramp Concerns Grow

      Abeona Therapeutics is back in focus after analysts cut their fair value estimate from about US$20.64 to roughly US$15.56, which meaningfully reshapes the implied upside in current models. This reset lines up with recent commentary that balances long term optimism around Zevaskyn with concern about slower commercial progress and the effect of dilution on the stock. As you read on, you will see how these price target moves fit into the broader Abeona Therapeutics story and what to watch as the...

      Nov 14Yahoo FinanceABEO
      Abeona Therapeutics Plans New Phase 3 Trial for ABO-801 as ZEVASKYN Launch Expands
      Nov 12Yahoo FinanceABEO
      Abeona at Stifel 2026 Healthcare Conference: launch gains and pipeline bet
      Nov 11Investing.comABEOSF
      Abeona Therapeutics Inc (ABEO) (Q3 2026) Earnings Call Highlights: ZivaSkin Revenue Jumps 18% ...

      Abeona Therapeutics Inc (ABEO) posted $13.5 million in ZivaSkin net revenue and added a Phase III-ready eosinophilic esophagitis candidate with peak sales potential exceeding $750 million.

      Nov 9Yahoo FinanceABEO
      Abeona Therapeutics Inc. Q3 2026 Earnings Call Summary
      Nov 9Yahoo FinanceABEO
      Abeona Therapeutics Acquires Late-Stage Drug Candidate, Secures $30 Million in Equity Financing
      Nov 9BenzingaABEO
      What Abeona Therapeutics (ABEO) Said on Its Q3 Earnings Call
      Nov 9Yahoo FinanceABEO
      Earnings call transcript: Abeona Therapeutics posts Q3 2026 EPS beat as stock falls
      Nov 9Investing.comABEO
      Abeona Therapeutics earnings beat by $0.10, revenue fell short of estimates
      Nov 9Investing.comABEO
      Abeona reports Q3 Zevaskyn revenue of $13.5 million
      Nov 9Investing.comABEO
      Abeona Therapeutics: Q3 Earnings Snapshot

      CLEVELAND (AP) — CLEVELAND (AP) — Abeona Therapeutics Inc. (ABEO) on Monday reported a loss of $4.

      Nov 9Yahoo FinanceABEO
      Abeona Therapeutics® Reports Third Quarter 2026 Financial Results and ZEVASKYN® Commercial Progress
      Nov 9Yahoo FinanceABEO
      Abeona Therapeutics® Acquires Phase 3-Ready APT-1011, Now ABO-801, and Enters Into Agreement for $30 Million Private Placement
      Nov 9Yahoo FinanceABEO
      Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      Nov 2Yahoo FinanceABEO
      Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      Oct 2Yahoo FinanceABEO
      Abeona Therapeutics CEO Seshadri sells $101,091 in shares
      Sep 30Investing.comABEO
      Abeona Therapeutics CFO Joseph Vazzano sells $47,385 in company stock
      Sep 30Investing.comABEO
      Abeona Therapeutics CCO Madhav sells $25,272 in stock
      Sep 30Investing.comABEO
      Abeona Therapeutics SVP sells $34,681 in company stock
      Sep 30Investing.comABEO
      Analysts Are Bullish on Top Healthcare Stocks: Abeona Therapeutics (ABEO), M3 (MTHRF)

      Detailed price information for Abeona Therapeutics (ABEO-Q) from The Globe and Mail including charting and trades.

      Sep 26The Globe and MailABEO
      Abeona Therapeutics stock reiterated at Buy by H.C. Wainwright
      Sep 25Investing.comABEO
      Abeona Therapeutics Highlights ZEVASKYN Launch Momentum, Revenue Growth at H.C. Wainwright

      Abeona Therapeutics (NASDAQ:ABEO) highlighted the early commercial progress of ZEVASKYN, its autologous gene-modified cellular sheet therapy for recessive dystrophic epidermolysis bullosa (RDEB), during the H.C. Wainwright 28th Annual conference. Madhav Vasanthavada, Abeona’s senior vice president

      Sep 22Yahoo FinanceABEO
      Abeona Expands ZEVASKYN Network as RDEB Launch Gains Momentum

      Abeona Therapeutics (NASDAQ:ABEO) executives outlined the early commercial rollout of ZEVASKYN, an autologous cell sheet-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), during the Morgan Stanley Global Healthcare Conference. Management emphasized that the launch requires a

      Sep 22Yahoo FinanceABEO
      Cantor raises Abeona stock price target on partner drug approval
      Sep 18Investing.comABEO
      Abeona Stands to Collect Royalties After Ultragenyx's FDA Approval — Here's the Rest of the Week
      Sep 18BenzingaABEORARE
      Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)
      Sep 18Yahoo FinanceABEOJBSSRARE
      ABEO Stock Gains On Approval For A Drug Abeona Sold, Rating For The One It Sells

      Abeona stands to collect mid-single-digit royalties on sales of Ultragenyx’s Fayuvi plus up to $30 million in commercial milestone payments as part of a licensing deal.

      Sep 17Yahoo FinanceABEORARE
      Roth/MKM initiates Abeona Therapeutics stock with buy rating
      Sep 17Investing.comABEO
      Abeona at morgan stanley healthcare conference: launch builds momentum
      Sep 16Investing.comABEOMS
      Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®

      CLEVELAND, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need, today announced the activation of University of Florida Health (UF Health) in Gainesville, Florida, as the eighth Qualified Treatment Center (QTC) for the administration of ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets. ZEVASKYN is the first and only autologous gene-modified c

      Sep 16Yahoo FinanceABEO
      Abeona Therapeutics Updates Investor Presentation at Conference

      Detailed price information for Abeona Therapeutics (ABEO-Q) from The Globe and Mail including charting and trades.

      Sep 16The Globe and MailABEO
      Abeona Therapeutics activates eighth treatment center for RDEB therapy
      Sep 16Investing.comABEO
      Abeona at Cantor healthcare conference: slow launch, big rare-disease bet
      Sep 9Investing.comABEO
      Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

      CLEVELAND, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in September 2026: Cantor Global Healthcare Conference 2026: Fireside chat on Wednesday, September 9, 2026, at 8:00 a.m. ET and investor meetings.H.C. Wainwright 28th Annual Global Investment Conference: Company presentation on Tuesday, September 15, 2026, at 12:00 p.m. ET and investor meetings.Morgan Stanley 2

      Sep 2Yahoo FinanceABEO
      Abeona Therapeutics director Mark Alvino sells $87,966 in shares
      Sep 2Investing.comABEO
      Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      CLEVELAND, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). On August 31, 2026, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to five individuals hired by Abeona, which equity awards relate to, in the

      Sep 1Yahoo FinanceABEO
      Abeona’s (ABEO) Gene Therapy Launch Hits A Pivotal Reimbursement Milestone

      On August 13, Abeona Therapeutics (NASDAQ:ABEO) reported second-quarter results that captured a company scaling a genuinely new kind of medicine while working through the bumps that come with it. ZEVASKYN, its cell therapy for a severe skin disease called recessive dystrophic epidermolysis bullosa, brought in $11.4 million in revenue for the quarter, and the number […]

      Aug 21Yahoo FinanceABEO

      This is the newest page. Registered accounts read further back.